Organization
The WIN Consortium is organized in the following groups who collectively work together to achieve WIN's common goals
“Transcriptomics in tumor and normal lung tissues identify early-stage NSCLC patients with high risk of post-surgery recurrence who may benefit from adjuvant therapies” Published by JCO Precision Oncology, ASCO
WINning together
WIN was formed on the premise that we can accomplish more together than each organization can achieve working alone. We aim to improve cancer patients’ survival and quality of life. View WIN's history and unique attributes:
-
01
WIN History -
02
Diversity of Stakeholders - WIN Members -
03
Studies with a diverse, gender equality global population -
04
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies and not-for-profit organizations.
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 35 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 35 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN is comprised of organizations representing all stakeholders in personalized cancer medicine.
WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health, patient advocacy and IT organizations.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health, patient advocacy and IT organizations.
Our members include 26 leading academic centers representing 18 countries and four continents, enabling coordinated studies with a global patient population.
The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.
WIN prioritizes cross-sector interaction designed to enhance learning across and between continents and healthcare sectors.
WIN Symposia, held annually, brings together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.
Clinical trials, projects and publications
WIN members collaboratively design and carry out global studies designed to achieve breakthroughs for patients worldwide. Our distinguished Scientific Advisory Board oversees WIN studies. Current trials include:
-
01
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments -
02
SPRING - Landmark Lung Cancer Tri-Therapy Clinical Trial -
03
WINTHER: the WIN Consortium's first global personalized medicine clinical trial, published in Nature Medicine -
04
WIN is currently developing the next generation of trials focused on lung cancer
“Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival”
WIN's article “Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival” published by NPJ Precision Oncology, a Nature Research journal.
SPRING 01 (Survival Prolongation by Rationale Innovative Genomics) proof of concept trial is the first trial exploring the tri-therapy strategy in first line of advanced/metastatic non-small cell lung cancer (NSCLC), following the historical success of this approach in AIDS and tuberculosis for which only tri-therapy demonstrated long term efficacy.
The WIN SPRING trial was conducted in the USA, France, Spain, Luxembourg and Israel in the following cancer centers: University of California - San Diego's Moores Cancer Center, Avera Cancer Center (Sioux Falls, Arizona), Institut Curie (Paris), Centre Léon Bérard (Lyon), Vall d'Hebron Institute of Oncology (Barcelona), Centre Hospitalier de Luxembourg (Luxembourg), and Chaim Sheba Medical Center (Israel).
The trial was sponsored by the WIN Consortium and funded by ARC Fondation for cancer research (France). The drugs were donated by Pfizer Inc.
The trial was sponsored by the WIN Consortium and funded by ARC Fondation for cancer research (France). The drugs were donated by Pfizer Inc.
Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium.
Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.
WIN is currently planning innovative global clinical trials that represent the next generation of studies focused on lung cancer.
European funded trials WINTHER EU FP7 funded and CHEMORES EU FP6 funded established foundations for WIN future global strategy for lung cancer currently under development.
The concept underlying the new strategy is developed in the following publications:
The concept underlying the new strategy is developed in the following publications:
People leadership
WIN leaders are selected for their contributions and commitment to making effective, personalized cancer medicine a reality for patients around the world. They guide WIN's strategic, operational, and scientific direction.
Organization
Chairman, WIN Consortium
Richard L. Schilsky
Richard L. Schilsky
Chairman, WIN Consortium; Professor Emeritus, University of Chicago; past President and former Executive Vice President & Chief Medical Officer (ASCO) (USA)
Vice Chairman, WIN Consortium
Josep Tabernero
Josep Tabernero
Vice Chairman, WIN Consortium; Head, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH); Director, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Chief Scientific and Operating Officer, WIN Consortium
Vladimir Lazar
Vladimir Lazar
Chief Scientific and Operating Officer, WIN Consortium
Director, Operational Team, WIN Consortium
Catherine Bresson
Catherine Bresson
Director, Operational Team, WIN Consortium
Our members
WIN members include 35 leading organizations representing all stakeholders in personalized cancer medicine covering 18 countries and 4 continents. Our shared vision is delivering the promise of effective, personalized cancer medicine to patients worldwide.
WIN Symposia
WIN Symposia, held annually, gathers leaders representing a breadth of stakeholders from around the world to learn, share, and collaborate. Visit http://www.winsymposium.org for registration and additional information.
WIN 2022 Symposium
October 29, 2022 - October 30, 2022REGISTER FOR WIN 2022 Symposium in Barcelona!
Don’t Miss Out! Less than 3 weeks to save with early bird rates!!
For further information, please visit our dedicated symposium website https://www.winsymposium.org!
Partnership JIPO and WIN
December 03, 2021 - December 03, 2022JIPO and WIN will cross-promote both organization’s activities throughout the year, including the WIN 2022 Symposium in Barcelona, Spain, October 29-30, 2022. Abstracts selected for presentation at the WIN meeting will be published in JIPO as a Conference Proceeding.
JIPO Editorial Fellow, Dr. Khalid Jazieh, will be interviewing members of WIN Leadership to highlight the collaboration and upcoming activities. Drs. Razelle Kurzrock, Vladimir Lazar, and Richard L. Schilsky will be interviewed. These interviews will be published on the JIPO YouTube channel in the coming weeks.
Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN, has been appointed to the JIPO Editorial Board to represent WIN Leadership. Dr. Lazar plans to contribute an editorial to the Journal in 2022. Dr. Kurzrock has published four articles in JIPO in 2019 and 2020.
WIN 2019 Symposium
June 23, 2019 - June 24, 2019The 11th edition of the WIN Symposia ‘WINnovation and Global Deployment of Precision Oncology’ took place in Paris, France on 23-24 June 2019.
Highlights and further information on the event, WIN 2019 can be found on our dedicated website at https://www.winsymposium.org/
What people are saying
"WIN is an unique, global, translational clinical research organization with a bold vision to bring cutting edge science and technology to the cure of cancer worldwide. It is a privilege to help guide the organization as Chairman." Richard L. Schilsky, WIN Chairman
"Achieving much needed major clinical breakthroughs in cancer treatment requires bold thinking and action, a can do attitude and winning spirit, and close collaboration of stakeholders and contributors with diverse background and expertise. All this is epitomized by WIN." Vladimir Lazar, Chief Scientific and Operating Officer
-
01
Survival-predicting algorithm passes first big test in patients with lung cancer -
02
JCO Precision Oncology: Transcriptomics in tumor and normal lung tissues identify early-stage NSCLC patients with high risk of post-surgery recurrence who may benefit from adjuvant therapies -
03
SPRING Phase I trial results published -
04
npj Precision Oncology: Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments
Survival-predicting algorithm passes first big test in patients with lung cancer
September 20, 2022
https://www.youtube.com/watch?v=1sXMWuoZbI0
https://www.youtube.com/watch?v=1sXMWuoZbI0
Transcriptomics in tumor and normal lung tissues identify early-stage NSCLC patients with high risk of post-surgery recurrence who may benefit from adjuvant therapies
JCO® Precision Oncology
September 15, 2022
Purpose
The prognosis of patients with non–small-cell lung cancer (NSCLC), traditionally determined by anatomic histology and TNM staging, neglects the biological features of the tumor that may be important in
determining patient outcome and guiding therapeutic interventions. Identifying patients with NSCLC at increased risk of recurrence after curative-intent surgery remains an important unmet need so that known effective adjuvant treatments can be offered to those at highest risk of recurrence.
Read the full article by downloading here:
Download pdf
September 15, 2022
Purpose
The prognosis of patients with non–small-cell lung cancer (NSCLC), traditionally determined by anatomic histology and TNM staging, neglects the biological features of the tumor that may be important in
determining patient outcome and guiding therapeutic interventions. Identifying patients with NSCLC at increased risk of recurrence after curative-intent surgery remains an important unmet need so that known effective adjuvant treatments can be offered to those at highest risk of recurrence.
Read the full article by downloading here:
Download pdf
Cancer Medicine Journal: A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer
Cancer Medicine, Wiley
March 20, 2022
Abstract
Background: The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define the cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal tissue biopsies. SPRING is the first trial to assess a SIMS-based tri-therapy regimen in advanced non-small cell lung cancer (NSCLC).
Cancer Med.
2022;00:1–11. doi: 10.1002/cam4.4635
View the full article: Download pdf
March 20, 2022
Abstract
Background: The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define the cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal tissue biopsies. SPRING is the first trial to assess a SIMS-based tri-therapy regimen in advanced non-small cell lung cancer (NSCLC).
Cancer Med.
2022;00:1–11. doi: 10.1002/cam4.4635
View the full article: Download pdf
npj Precision Oncology Publication of "Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival”
NPJ Precision Oncology, a Nature Research journal
Apr 28, 2021
Abstract
The expanding targeted therapy landscape requires combinatorial biomarkers for patient stratification and treatment selection. This requires simultaneous exploration of multiple genes of relevant networks to account for the complexity of mechanisms that govern drug sensitivity and predict clinical outcomes. We present the algorithm, Digital Display Precision Predictor (DDPP), aiming to identify transcriptomic predictors of treatment outcome. For example, 17 and 13 key genes were derived from the literature by their association with MTOR and angiogenesis pathways, respectively, and their expression in tumor versus normal tissues was associated with the progression-free survival (PFS) of patients treated with everolimus or axitinib (respectively) using DDPP. A specific eight-gene set best correlated with PFS in six patients treated with everolimus: AKT2, TSC1, FKB-12, TSC2, RPTOR, RHEB, PIK3CA, and PIK3CB (r = 0.99, p = 5.67E−05). A two-gene set best correlated with PFS in five patients treated with axitinib: KIT and KITLG (r = 0.99, p = 4.68E−04). Leave-one-out experiments demonstrated significant concordance between observed and DDPP predicted PFS (r = 0.9, p = 0.015) for patients treated with everolimus. Notwithstanding the small cohort and pending further prospective validation, the prototype of DDPP offers the potential to transform patients’ treatment selection with a tumor- and treatment-agnostic predictor of outcomes (duration of PFS).
npj Precision Oncology (2021)5:33;
https://doi.org/10.1038/s41698-021-00171-6
Download the full article here: Download pdf
===============================================
WIN Press Release
VILLEJUIF, FRANCE, April 30, 2021
EINPresswire.com
The Worldwide Innovative Network in personalized cancer medicine consortium - WIN Consortium announces the publication of the Digital Display Precision Predictor: the
prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in NPJ Precision Oncology (10.1038/s41698- 021-00171-6).
Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient’s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic
approach used for most targeted therapies provides limited treatment options, with a binary "yes/no" expected response to a drug and no recommendation for which treatment, among a
range of possible options, is likely to be the best option for a particular patient.
The Digital Display Precision Predictor (DDPP), is a biomarker strategy and tool able to predict the duration of progression-free survival (PFS) for multiple targeted treatments for patients with advanced/metastatic cancers, based on the comprehensive investigation of the whole
transcriptome (the gene expression profile of the tumor compared to that of normal tissue).
DDPP is based on: 1) the exploration of the whole transcriptome (20,000 genes) providing insight about the status of activation of almost all drug targets in the context of the network of genes or pathways that drive tumor progression; 2) the data can be obtained from a single assessment requiring very small amounts of tumor and analogous normal tissues; and 3) the prediction of the duration of the time until tumor progression (PFS) under a specific therapeutic regimen.
"One of the main challenges of finding new biomarkers is that they are built in a relatively small number of patients treated with the same drug (from the WINTHER trial), for whom both molecular profiles (from tumor and analogous normal tissues) and PFS data were available," said Dr. Josep Tabernero, Vice-Chairman and Chairman of Scientific Advisory Board of WIN, Director, Vall d'Hebron Institute of Oncology, VHIO (Spain) and past ESMO President (2018-2019).
"The DDPP is potentially a new global biomarker tool that can apply to any type of cancer drug used alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer," concluded Dr. Richard L. Schilsky, Chairman of WIN.
Download the press release: Download pdf
© 1995-2021 IPD Group, Inc. All Rights Reserved
Apr 28, 2021
Abstract
The expanding targeted therapy landscape requires combinatorial biomarkers for patient stratification and treatment selection. This requires simultaneous exploration of multiple genes of relevant networks to account for the complexity of mechanisms that govern drug sensitivity and predict clinical outcomes. We present the algorithm, Digital Display Precision Predictor (DDPP), aiming to identify transcriptomic predictors of treatment outcome. For example, 17 and 13 key genes were derived from the literature by their association with MTOR and angiogenesis pathways, respectively, and their expression in tumor versus normal tissues was associated with the progression-free survival (PFS) of patients treated with everolimus or axitinib (respectively) using DDPP. A specific eight-gene set best correlated with PFS in six patients treated with everolimus: AKT2, TSC1, FKB-12, TSC2, RPTOR, RHEB, PIK3CA, and PIK3CB (r = 0.99, p = 5.67E−05). A two-gene set best correlated with PFS in five patients treated with axitinib: KIT and KITLG (r = 0.99, p = 4.68E−04). Leave-one-out experiments demonstrated significant concordance between observed and DDPP predicted PFS (r = 0.9, p = 0.015) for patients treated with everolimus. Notwithstanding the small cohort and pending further prospective validation, the prototype of DDPP offers the potential to transform patients’ treatment selection with a tumor- and treatment-agnostic predictor of outcomes (duration of PFS).
npj Precision Oncology (2021)5:33;
https://doi.org/10.1038/s41698-021-00171-6
Download the full article here: Download pdf
===============================================
WIN Press Release
VILLEJUIF, FRANCE, April 30, 2021
EINPresswire.com
The Worldwide Innovative Network in personalized cancer medicine consortium - WIN Consortium announces the publication of the Digital Display Precision Predictor: the
prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in NPJ Precision Oncology (10.1038/s41698- 021-00171-6).
Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient’s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic
approach used for most targeted therapies provides limited treatment options, with a binary "yes/no" expected response to a drug and no recommendation for which treatment, among a
range of possible options, is likely to be the best option for a particular patient.
The Digital Display Precision Predictor (DDPP), is a biomarker strategy and tool able to predict the duration of progression-free survival (PFS) for multiple targeted treatments for patients with advanced/metastatic cancers, based on the comprehensive investigation of the whole
transcriptome (the gene expression profile of the tumor compared to that of normal tissue).
DDPP is based on: 1) the exploration of the whole transcriptome (20,000 genes) providing insight about the status of activation of almost all drug targets in the context of the network of genes or pathways that drive tumor progression; 2) the data can be obtained from a single assessment requiring very small amounts of tumor and analogous normal tissues; and 3) the prediction of the duration of the time until tumor progression (PFS) under a specific therapeutic regimen.
"One of the main challenges of finding new biomarkers is that they are built in a relatively small number of patients treated with the same drug (from the WINTHER trial), for whom both molecular profiles (from tumor and analogous normal tissues) and PFS data were available," said Dr. Josep Tabernero, Vice-Chairman and Chairman of Scientific Advisory Board of WIN, Director, Vall d'Hebron Institute of Oncology, VHIO (Spain) and past ESMO President (2018-2019).
"The DDPP is potentially a new global biomarker tool that can apply to any type of cancer drug used alone or in combination, agnostic of tumor type, and can lead, pending further prospective validation, to a new approach to optimal treatment selection for patients with cancer," concluded Dr. Richard L. Schilsky, Chairman of WIN.
Download the press release: Download pdf
© 1995-2021 IPD Group, Inc. All Rights Reserved